Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Luca SalaAndrea Alberti

Abstract

Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI) showing longer progression free survival and overall survival than other EGFR-TKI with an improvement in tolerability. We report about an advanced lung adenocarcinoma patient with severe aplastic anemia during first line osimertinib. Severe hematologic toxicity is extremely rare but possible with osimertinib and clinicians should be careful about changes in blood cell count during the use of it.

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.